380 related articles for article (PubMed ID: 26018967)
1. A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.
Saulnier Sholler GL; Gerner EW; Bergendahl G; MacArthur RB; VanderWerff A; Ashikaga T; Bond JP; Ferguson W; Roberts W; Wada RK; Eslin D; Kraveka JM; Kaplan J; Mitchell D; Parikh NS; Neville K; Sender L; Higgins T; Kawakita M; Hiramatsu K; Moriya SS; Bachmann AS
PLoS One; 2015; 10(5):e0127246. PubMed ID: 26018967
[TBL] [Abstract][Full Text] [Related]
2. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport.
Samal K; Zhao P; Kendzicky A; Yco LP; McClung H; Gerner E; Burns M; Bachmann AS; Sholler G
Int J Cancer; 2013 Sep; 133(6):1323-33. PubMed ID: 23457004
[TBL] [Abstract][Full Text] [Related]
3. Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma.
Schultz CR; Swanson MA; Dowling TC; Bachmann AS
Cancer Chemother Pharmacol; 2021 Oct; 88(4):607-617. PubMed ID: 34129075
[TBL] [Abstract][Full Text] [Related]
4. Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma.
Koomoa DL; Yco LP; Borsics T; Wallick CJ; Bachmann AS
Cancer Res; 2008 Dec; 68(23):9825-31. PubMed ID: 19047162
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine.
Love RR; Carbone PP; Verma AK; Gilmore D; Carey P; Tutsch KD; Pomplun M; Wilding G
J Natl Cancer Inst; 1993 May; 85(9):732-7. PubMed ID: 8478959
[TBL] [Abstract][Full Text] [Related]
6. Polyamines as biomarkers of cervical intraepithelial neoplasia.
Nishioka K; Melgarejo AB; Lyon RR; Mitchell MF
J Cell Biochem Suppl; 1995; 23():87-95. PubMed ID: 8747382
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the polyamine synthesis enzyme ornithine decarboxylase sensitizes triple-negative breast cancer cells to cytotoxic chemotherapy.
Geck RC; Foley JR; Murray Stewart T; Asara JM; Casero RA; Toker A
J Biol Chem; 2020 May; 295(19):6263-6277. PubMed ID: 32139506
[TBL] [Abstract][Full Text] [Related]
8. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.
Rounbehler RJ; Li W; Hall MA; Yang C; Fallahi M; Cleveland JL
Cancer Res; 2009 Jan; 69(2):547-53. PubMed ID: 19147568
[TBL] [Abstract][Full Text] [Related]
9. Targeting ornithine decarboxylase reverses the LIN28/Let-7 axis and inhibits glycolytic metabolism in neuroblastoma.
Lozier AM; Rich ME; Grawe AP; Peck AS; Zhao P; Chang AT; Bond JP; Sholler GS
Oncotarget; 2015 Jan; 6(1):196-206. PubMed ID: 25415050
[TBL] [Abstract][Full Text] [Related]
10. Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.
Carbone PP; Douglas JA; Larson PO; Verma AK; Blair IA; Pomplun M; Tutsch KD
Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):907-12. PubMed ID: 9796636
[TBL] [Abstract][Full Text] [Related]
11. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention.
Meyskens FL; Gerner EW; Emerson S; Pelot D; Durbin T; Doyle K; Lagerberg W
J Natl Cancer Inst; 1998 Aug; 90(16):1212-8. PubMed ID: 9719082
[TBL] [Abstract][Full Text] [Related]
12. Difluoromethylornithine Combined with a Polyamine Transport Inhibitor Is Effective against Gemcitabine Resistant Pancreatic Cancer.
Gitto SB; Pandey V; Oyer JL; Copik AJ; Hogan FC; Phanstiel O; Altomare DA
Mol Pharm; 2018 Feb; 15(2):369-376. PubMed ID: 29299930
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine.
Qu N; Ignatenko NA; Yamauchi P; Stringer DE; Levenson C; Shannon P; Perrin S; Gerner EW
Biochem J; 2003 Oct; 375(Pt 2):465-70. PubMed ID: 12859253
[TBL] [Abstract][Full Text] [Related]
14. The effects of DFMO on polyamine metabolism in the inner ear.
Marks SC; Mattox DE; Casero RA
Hear Res; 1991 Jun; 53(2):230-6. PubMed ID: 1880077
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of polyamine biosynthesis preserves β cell function in type 1 diabetes.
Sims EK; Kulkarni A; Hull A; Woerner SE; Cabrera S; Mastrandrea LD; Hammoud B; Sarkar S; Nakayasu ES; Mastracci TL; Perkins SM; Ouyang F; Webb-Robertson BJ; Enriquez JR; Tersey SA; Evans-Molina C; Long SA; Blanchfield L; Gerner EW; Mirmira RG; DiMeglio LA
Cell Rep Med; 2023 Nov; 4(11):101261. PubMed ID: 37918404
[TBL] [Abstract][Full Text] [Related]
16. Synergistic drug combination GC7/DFMO suppresses hypusine/spermidine-dependent eIF5A activation and induces apoptotic cell death in neuroblastoma.
Schultz CR; Geerts D; Mooney M; El-Khawaja R; Koster J; Bachmann AS
Biochem J; 2018 Jan; 475(2):531-545. PubMed ID: 29295892
[TBL] [Abstract][Full Text] [Related]
17. Biochemical changes associated with alpha-difluoromethylornithine uptake and resistance in Trypanosoma brucei.
Bellofatto V; Fairlamb AH; Henderson GB; Cross GA
Mol Biochem Parasitol; 1987 Oct; 25(3):227-38. PubMed ID: 3122042
[TBL] [Abstract][Full Text] [Related]
18. Characterising the Response of Human Breast Cancer Cells to Polyamine Modulation.
Akinyele O; Wallace HM
Biomolecules; 2021 May; 11(5):. PubMed ID: 34067619
[TBL] [Abstract][Full Text] [Related]
19. Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells.
Wallick CJ; Gamper I; Thorne M; Feith DJ; Takasaki KY; Wilson SM; Seki JA; Pegg AE; Byus CV; Bachmann AS
Oncogene; 2005 Aug; 24(36):5606-18. PubMed ID: 16007177
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of lupus nephritis in MRL-lpr/lpr mice by inhibiting ornithine decarboxylase.
Gunnia UB; Amenta PS; Seibold JR; Thomas TJ
Kidney Int; 1991 May; 39(5):882-90. PubMed ID: 2067204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
